Pall Corp. (NYSE: PLL) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in PLL indicates that the price change in the extended hours is…
Shares of Cardica (NASDAQ:CRDC) climbed in Thursday’s pre-market session, after the developer of endoscopic microcutter products said it received 510(k) clearance from the U.S. Food and Drug Administration for its MicroCutter XCHANGE 30 white cartridge and for an additional plastic material contained within the MicroCutter XCHANGE 30 blue cartridge for use in medium-thickness tissue. The…
Specialty foundry company Tower Semiconductor Ltd. (NASDAQ:TSEM) reports non-GAAP diluted EPS of $0.34 for Q4 2013, up sequentially from $0.22 in Q3 2013. Two analysts surveyed by Capital IQ called for non-GAAP diluted EPS of $0.29. Revenue was down 2% from Q3 2013 to $134.6 million, falling short of the $140 million Capital IQ consensus….
Autodesk Inc. (NASDAQ:ADSK) rose 4.2% in extended trading after reporting earnings that beat analyst estimates. The software company’s Q4 earnings fell 25% from a year earlier to $0.40 a share, beating the Capital IQ estimate of $0.34. Revenue slipped 3.4% from a year earlier $586.6 million, beating the consensus estimate of $571 million. Autodesk estimated…
Real estate investment trust American Tower (NYSE:AMT) is preparing a bid for an Indian telecommunications tower company, Viom Networks, that could amount to $1.6 billion to $1.9 billion, according to the Economic Times, an Indian newspaper. Citing unnamed sources, the Times said the bid may come by March 7, and that American Tower is likely…
Aegerion Pharmaceuticals (NASDAQ:AEGR) is lower after it reported a Q4 loss that was smaller than analysts had expected and set a FY14 sales guidance that straddled estimates. Shares are down 11.48% at $58.73 with a 52-week range of $28.33 – $101.00. In the quarter, the biopharmaceutical company had a non-GAAP loss of $0.14 per share,…
